Company Spotlight: Cue Biopharma Innovates in the Immunotherapy Space with its Immuno-STAT Platform
XTalks
AUGUST 17, 2020
The peptide HLA allows the Immuno-STAT to be targeted to the right T cells – it is essentially the address of where it should go to as opposed to broadly suppressing the immune system, which has liabilities and is counterproductive as it makes patients susceptible to infectious diseases and cancers, explains Dr. Suri. Neo-STAT Platform.
Let's personalize your content